Rationale: Monoamine oxidases (MAOs) are mitochondrial enzymes that catabolize prohypertrophic neurotransmitters, such as norepinephrine and serotonin, generating hydrogen peroxide. Because excess reactive oxygen species and catecholamines are major contributors to the pathophysiology of congestive heart failure, MAOs could play an important role in this process. Objective: Here, we investigated the role of MAO-A in maladaptive hypertrophy and heart failure. Methods and Results: We report that MAO-A activity is triggered in isolated neonatal and adult myocytes on stimulation with norepinephrine, followed by increase in cell size, reactive oxygen species production, and signs of maladaptive hypertrophy. All of these in vitro changes occur, in part, independently from ␣and ␤-adrenergic receptor-operated signaling and are inhibited by the specific MAO-A inhibitor clorgyline. In mice with left ventricular dilation and pump failure attributable to pressure overload, norepinephrine catabolism by MAO-A is increased accompanied by exacerbated oxidative stress. MAO-A inhibition prevents these changes, and also reverses fetal gene reprogramming, metalloproteinase and caspase-3 activation, as well as myocardial apoptosis. The specific role of MAO-A was further tested in mice expressing a dominant-negative MAO-A (MAO-A neo ), which were more protected against pressure overload than their wild-type littermates. Conclusions: In addition to adrenergic receptor-dependent mechanisms, enhanced MAO-A activity coupled with increased intramyocardial norepinephrine availability results in augmented reactive oxygen species generation, contributing to maladaptive remodeling and left ventricular dysfunction in hearts subjected to chronic stress. (Circ Res. 2010;106:193-202.)
H emodynamic overload leads to increased cardiac mass and cardiomyocyte volume associated with characteristic changes in gene and protein expression. This initial compensatory hypertrophy is replaced by progressive structural/functional cardiac remodeling involving alterations in extracellular matrix composition, myocardial energetics, Ca 2ϩ cycling, and myocyte viability. [1] [2] [3] [4] Reactive oxygen species (ROS) contribute to each of these abnormalities, [5] [6] [7] [8] [9] [10] but relevant sources of ROS remain to be fully defined. This is important, because recent studies suggest that specific targeting of ROS sources provides a more effective therapy for heart remodeling. 11 Monoamine oxidases (MAOs) are mitochondrial flavoenzymes which catalyze oxidative deamination of catecholamines (CAs) and biogenic amines such as serotonin. During this process, they generate hydrogen peroxide (H 2 O 2 ) and thus can potentially be a source of oxidative stress in the heart, particularly under stress conditions. Yet, although the role of MAOs in terminating neurotransmitter signaling in the brain is well established, 12 little is known about its modulation of cardiac morphology and function. MAOs exist in 2 isoforms, MAO-A and -B, with distinct substrate and inhibitor sensitivity. 12 MAO-A, in particular, is present in the myocardium of several species from humans to rodents, [13] [14] [15] where it principally catabolizes serotonin, norepinephrine (NE) and epinephrine. All of these monoamine neurotransmitters have major functional implications in the heart, especially in the modulation of cardiac inotropy. A role for MAO-A and serotonin in ischemic/reperfused myocardium has been delineated showing that inhibiting MAO-A countermands oxidative stress, neutrophil accumulation and mitochondria-dependent cell death. 16 Yet, the involvement of MAO-A and its impact on neurotransmitter availability in congestive heart failure (CHF) remains poorly defined, although one could speculate that this is the type of setting wherein MAO-A might be chiefly at play. CHF is accompanied by enhanced sympathetic tone, 17 excess circulating CAs such as NE, 18 and increased oxidative stress. 19 In such situations, MAO-A may be upregulated, generating greater amounts of H 2 O 2 thus exacerbating disease progression.
Here, we first determined whether cardiomyocyte (both neonatal and adult) exposure to NE is coupled to augmented MAO-A expression/activity, which in turn regulates a hypertrophic response linked to the generation of intracellular ROS. Adrenergic receptor-independent signaling was assessed using the MAO substrate tyramine. Second, we hypothesized that persistent hemodynamic stress imposed by in vivo pressure overload leads to excess CAs (and/or serotonin) presence at the myocyte surface resulting in increased sarcolemmal transport via extraneuronal monoamine transporter, 20,21 thus enhancing substrate availability for intramyocyte MAO-A activity. To test this, we subjected mice to transverse aortic constriction (TAC), in the absence and presence of the highly selective MAO-A inhibitor clorgyline, 22 and in mice expressing a dominant negative MAO-A (MAO-A neo ). Here, we show that NE triggers ROS and myocyte hypertrophy in part by a MAO-A dependent mechanism in vitro. In vivo, NE catabolism and ROS production are markedly upregulated in pressure overloaded hearts and both effects are ameliorated by inhibiting MAO-A activity to suppress cardiac decompensation with pressure overload.
Methods

Animals
For pharmacological studies, male C57BL/6 mice (nϭ30, 9 to 11 weeks old) were used and clorgyline was administered using saline as vehicle (1 mg/kg per day, IP). For experiments using genetically modified mice, MAO-A neo mice and their wild-type (WT) littermates in 129/Sv background were used (nϭ30). The Johns Hopkins University Institutional Animal Care and Use Committee approved all animal experiments.
Statistics
All values are expressed as meansϮSEM. Comparison between groups was performed by 1-way or 2-way ANOVA, followed by a Tukey's post hoc multiple comparison test. Comparisons between two groups were performed using nonpaired 2-tailed Student t test. A value of PϽ0.05 was considered significant.
An expanded Methods section is available in the Online Data Supplement at http://circres.ahajournals.org.
Results
Norepinephrine Triggers Cardiomyocyte Maladaptive Hypertrophy in a MAO-A-Dependent Manner
We first tested whether externally applied NE (as when released from varicosities into the neuroeffector junctional areas) can enter myocytes, stimulating MAO-A activity and ROS-dependent signaling. Cultured rat neonatal cardiomyocytes were incubated with NE (10 mol/L, 24 hours), which resulted in cell hypertrophy indexed by increased brain natriuretic peptide (BNP) gene expression and 1.3-fold increase in myocyte area ( Figure 1A and 1B ). This effect was accompanied by a rise in MAO-A gene expression and associated with a markedly increased production of mitochondrial ROS, measured with Mitotracker Red ( Figure 1C and 1D). In these same experimental conditions, mitochondrial membrane potential was unchanged (Online Figure IV) . Coincubation with the selective MAO-A inhibitor clorgyline 23 (2 mol/L) significantly blunted NE-induced ROS production and myocyte hypertrophy ( Figure 1A , 1B, and 1D). Similar inhibition was obtained with 5 mol/L clorgyline (40% to 50%, data not shown). To test the contribution of adrenergic receptor signaling, myocytes were incubated with tyramine, a MAO substrate that does not interact with adrenergic receptors yet is also transported into cells via the extraneuronal monoamine transporter. 24 Myocytes treated with tyramine for 24 hours displayed a marked increase in mitochondrial oxidative stress ( Figure 1D ), and clorgyline prevented this change. Tyramine also increased myocyte area and BNP ( Figure 1E and 1F), NFAT3 (nuclear factor of activated T cells), and NFAT4 ( Figure  1G ) gene expression; the latter are transcription factors implicated in maladaptive hypertrophy. 25 Clorgyline inhibited tyramine-induced hypertrophy and suppressed increases in BNP and NFAT expression induced by either NE or tyramine.
We further tested these effects in adult cultured myocytes isolated from WT and MAO-A neo mice, the latter expressing a dominant negative MAO-A, resulting in only 8% of residual MAO-A catalytic activity. WT myocytes challenged with NE displayed a marked arise in ROS production and this was significantly less in myocytes from MAO-A neo mice Figure 2A) . Likewise, increased cell area from NE exposure in WT myocytes was reduced in those from MAO-A neo hearts ( Figure 2B ). These data further support the hypothesis that, in addition to adrenergic receptors, MAO-A derived ROS also contribute to NE-induced hypertrophy. The fact that in 2 different systems (neonatal rat and adult mouse myocytes) clorgyline or the genetic suppression of MAO-A activity produced a nearly equal reduction in ROS production and hypertrophy validates clorgyline as a specific MAO-A inhibitor.
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Norepinephrine Catabolism Is Increased in Failing (TAC) Hearts Because of Enhanced MAO-A Activity
We next tested whether these findings pertained in vivo. Mice were subjected to TAC and MAO-A gene expression/activity was examined. As expected, 19 TAC increased left ventricle (LV) mass/body weight ratio (ϩ330% versus sham, PϽ0.001), chamber dilation, and LV dysfunction, all features of adverse remodeling (Table 1 ). In these hearts, MAO-A gene expression was 3-fold higher ( Figure 3A , top). To test for MAO-A activity, we initially performed in vitro activity assays using 14 C-labeled serotonin as a substrate. No significant differences were observed after 6 weeks of TAC versus sham-controls ( Figure 3A , bottom). MAO activity was also indexed by H 2 O 2 production in tissue homogenates in the presence of substrates. Again, no difference was evident (data not shown). To test whether MAO-A activity was upregulated in vivo as a result of increased substrate availability, we measured cardiac NE and serotonin levels in LV specimens of sham and TAC mice. We also assessed the absolute content of dihydroxyphenylglycol (DHPG) and 5-hydroxyindoleacetic acid (5-HIAA) that are the primary catabolic products of NE and serotonin, respectively, resulting from reactions catalyzed by MAO-A. 26 Absolute cardiac amount of DHPG was significantly elevated in LV tissue extracts of TAC mice, with a consistent marked decrease in cardiac NE content ( Figure 3B ). When cardiac DHPG content was normalized to intracardiac NE levels, the DHPG/NE ratio was 4-fold higher in TAC hearts versus shams ( Figure 3B ). Thus, in TAC hearts NE catabolism is increased. Evidence showing that MAO-A inhibition by clorgyline fully reverted the rise in DHPG and DHPG/NE ratio while rescuing the intracardiac content of NE available for release ( Figure 3B ) supports the specific involvement of MAO-A in this setting.
We also determined whether serotonin, another elective MAO-A substrate, is equally important in this CHF model. Serotonin levels were unaltered by TAC, and rose only after clorgyline treatment, consistent with MAO-A inhibition (Figure 3C ). In stark contrast to DHPG, serotonin catabolism measured by 5-HIAA and 5-HIAA/serotonin ratio was not altered in TAC hearts compared to shams. However, clorgyline significantly reduced 5-HIAA/serotonin ratio after TAC. Together, these data show NE to be the preferred substrate fueling MAO-A activity in this model. Intriguingly, the protein expression of the neuronal NE transporter (NET) declined with TAC, likely reducing neuronal NE reuptake. Clorgyline treated TAC mice had normal NET expression ( Figure 3D ) and higher neuronal NE levels.
MAO-A Inhibition Prevents LV Dilation and Dysfunction in TAC Hearts
We next examined whether MAO-A inhibition was also effective in blunting maladaptive responses to sustained pressure overload in vivo. After 3 weeks of TAC, both salineand clorgyline-treated hearts developed increased wall thickness, but the latter hearts also had preserved LV function: fractional shortening and ejection fraction values were indeed similar to those reported for sham-controls (Table 1) . This beneficial impact on cardiac structure and function became even more pronounced 6 weeks after TAC. Heart weight to body weight ratio was significantly reduced in the clorgylinegroup ( Figure 4B) , and end-diastolic and end-systolic dimen-sions were less and not dissimilar from values seen in sham-operated mice ( Table 1 and Figure 1A) . Cardiac function was also fully preserved. Pressure-volume (PV) analysis was also performed to assess if clorgyline had any effects on basal cardiac function over the same time-course of treatment. We found no differences (Online Figure I) .
Maladaptive hypertrophy is typically paralleled by fetal gene reprogramming with increased cardiac expression of atrial natriuretic peptide, BNP, and myosin heavy chain ␤ (␤-MHC). 25 Therefore, we tested whether clorgyline treatment restored the adult phenotype expression. LV mRNA expression for atrial natriuretic peptide, BNP and ␤-MHC increased markedly in TAC hearts ( Figure 4C ), and clorgyline treatment lowered expression of all genes by 2-fold. Thus, MAO-A inhibition prevents both adverse cardiac structural and gene reprogramming in pressure-overloaded hearts.
Oxidative Stress, Matrix Metalloproteinase Activation, and Apoptosis Are Blunted in Clorgyline-Treated TAC Hearts
Altered cardiac tissue redox balance is a hallmark of CHF, 6, 10 and MAO-A is a recognized source of ROS in ischemia/ reperfusion injury. 16, 27 Yet, whether MAO-A upregulation contributes to CHF pathophysiology in part via enhanced oxidative stress is unknown. Consistent with previous reports, 19 ROS were markedly elevated in myocardium of 6-weeks TAC mice detected by dihydroethidium staining ( Figure 5A ). This burden was significantly reduced by clorgyline. Results were further confirmed by measuring tissue malondialdehyde, an index of lipid peroxidation. Malondialdehyde amount in TAC hearts was significantly lower after MAO-A inhibition ( Figure 5B ).
Because ROS are among the activators of gelatinases such as matrix metalloproteinase (MMP)-2 and MMP-9 and MMPs are upregulated in pressure-overloaded hearts, 19 we tested whether this was also suppressed by clorgyline. Activities of both MMP-2 and MMP-9 were upregulated in TAC hearts, and clorgyline reduced this ( Figure 5C ). We also tested whether myocardial apoptosis was involved in TACinduced CHF and blunted by clorgyline. Cleaved (activated) caspase-3 ( Figure 5D ) and the number of apoptotic cells measured by TUNEL assay ( Figure 5E ) markedly rose after 6 weeks of TAC. Clorgyline significantly blunted these adverse phenomena.
MAO-A neo Mice Display Improved LV Function, No Chamber Dilation, and Reduced Levels of Fibrosis After TAC
To further establish the specific involvement of MAO-A in TAC-induced cardiac remodeling, we studied mice lacking enzyme activity because of expression of a dominant negative MAO-A (MAO-A neo ). These mice display almost null MAO-A activity ( Figure 6A ) but have preserved levels and activity of MAO-B (Online Figure II) . The cardiac phenotype of these mice had yet to be fully characterized, thus loadindependent LV function and hemodynamics were examined using in vivo PV relationships. WT and MAO-A neo mice were somewhat different at baseline, with LV systolic pressure, dP/dt max , and dP/dt min all lower in MAO-A neo compared to WT littermates ( Table 2 ). Contractile function assessed by preload recruitable stroke work index was also lower in MAO-A neo mice, so these differences were potentially related to loading changes. However, chamber volume and ejection fraction were similar between the two strains. When WT and MAO-A neo mice were subjected to 9 week of TAC, WT hearts had a greater dilation, with a rightward shift in the PV loop ( Figure 6A and 6B) , whereas LV function became impaired. In contrast, MAO-A neo mice showed a slight leftward shift of the PV relations, with preserved (basal) cardiac volumes, and maintained cardiac function. Consistent with the data obtained in C57BL/6 mice, 129/Sv WT mice also displayed reduced NET protein abundance after CHF. In stark contrast, NET levels in MAO-A neo mice were similar to those reported for sham operated mice ( Figure 6C ). Compared to WT, MAO-A neo mice subjected to TAC also had less interstitial fibrosis ( Figure 6D ). Thus, genetic inhibition of MAO-A activity also helped ameliorate structural/functional consequences of chronic pressure overload.
Discussion
Changes in cardiac tissue redox balance participate in myocyte hypertrophy and failure, influencing extracellular matrix remodeling, Ca 2ϩ handling, and metabolic substrate. 6,10,28 Clarification of the important sources of ROS therefore has pathogenetic and therapeutic relevance. In the cytosol, NADPH oxidase, xanthine oxidase, and uncoupled nitric oxide synthase are recognized ROS sources. 10, 19, 29 Mitochondria are another major source, 30, 31 largely from the respiratory chain and p66 Shc , 32 and are known to contribute to ischemia/ reperfusion injury. 33 Within mitochondria, the flavoenzyme MAO-A, located in the outer membrane of the organelle, is a major ROS generator. MAO-A activity is implicated in serotonin-induced myocyte apoptosis 16 and ischemia/reperfusion injury via a ROS-dependent process involving sphingosine kinase inhibition and accumulation of ceramide. 27 MAO-derived ROS also appear relevant to serotonininduced myocyte hypertrophy in vitro. 34 In this study, we showed that in addition to serotonin, NE catabolism by MAO-A plays a prominent role in hypertrophy in vitro and in its progression toward heart failure in vivo. Catecholamines, and NE in particular, are known to contribute to cardiac disease and couple to ROS signaling. 35 Enhanced CA synthesis and release may provide help for adaptation to increased workload; however, because NE is a high affinity substrate for MAO-A, 36, 37 this can also serve as a major factor for increased ROS, as supported by our in vitro myocyte data. Clorgyline partly prevented this change, whereas the remaining prooxidant/hypertrophic effects were likely attributable to adrenergic receptor-coupled mechanisms. 35 Furthermore, NE metabolism by MAO-A increased in TAC mice, which was also associated with exacerbated oxidative stress, chamber dilation, and reduced systolic function. Pharmacological inhibition of MAO-A suppressed these changes.
Impairment of NE neuronal reuptake and concomitant downregulation of the ␤-adrenergic system are well documented in human and experimental CHF, 38 contributing to the loss of systolic performance in this syndrome. In normal hearts, 92% of the NE released by sympathetic nerves is recaptured by NET, 4% is removed by extraneuronal uptake, and the remaining 4% enters the circulation. 18 However, NET function declines in CHF, 39, 40 resulting in NE spillover and extraneuronal uptake which almost doubles in CHF patients. 18 Also, the balance between vesicular NE sequestration (which represents the "measurable" NE pool) and leakage in the intracardiac sympathetic efferent fibers may be altered to favor extraneuronal uptake, 41 providing more substrate for MAO-A. The present results showing reduced NET expression in TAC hearts support this hypothesis. Increased ROS generation could stem from intramyocyte and/or intraneuronal MAO-A activity as clorgyline inhibits both. The former is supported by the present findings (eg, Figures 1 and 5A and 5B), whereas proof of the latter would require studies in isolated sympathetic efferent fibers and/or nerve-muscle preparations. Our data also showed that clorgyline or genetic ablation of MAO-A catalytic activity restored NET expression back to control levels in TAC hearts, consistent with findings that systemic administration of MAO inhibitors increases the number of NET recognition sites. 42 This finding hints at the possibility that MAO-A inhibition may also benefit both NE reuptake and intraneuronal CAs recycle for rerelease, thereby reducing requirements for transmitter neosynthesis. 20 Prior evidence for MAO-A involvement in cardiac remodeling derives largely from microarray analyses, showing changes in gene expression in models such as high-salt diet and myocardial infarction. 43 More recently, the role of MAO-A was explored in pressure overload-induced hypertrophy. 44 In that study, Lairez et al showed a role of enhanced serotonin signaling via the serotonin receptor 2A (5-hydroxytryptamine 2A [5-HT 2A ]) and found that although antagonizing 5-HT 2A was beneficial, genetic deletion of MAO-A proved detrimental, exacerbating LV thickening and fibrosis. Although differences in the models could underlie the apparent contradiction with the present findings, other factors might also contribute, such as the severity of the pressure overload. In the prior study, even the WT mice showed little dilation and preserved function. The authors also used WT as opposed to littermate controls (the latter employed in the present study). The C57BL/6 strain develops more severe responses to TAC, and the benefits of clorgyline, which avoids potential adaptive changes in the MAO-A gene deletion mouse models, supports the opposite response. Although our control mice for the MAO-A neo studies (129/Sv background) developed less hypertrophy (consistent with prior reports 45 ), there was still substantial dilation that was ameliorated in mice lacking active MAO-A. Other potential contributors to this discrepancy are difference in functional assessment, with anesthesia-induced cardiodepression in the earlier study, versus conscious data in the present experiments. MAO-A neo mice also had basal elevated intracardiac NE content. It remains to be determined whether myocytespecific gene deletion would yield the same results. In the earlier study of Lairez et al, 44 cardiac levels of CAs were not determined whereas serotonin levels were found to be increased at baseline in MAO-A Ϫ/Ϫ mice, consistent with present findings, and did not change when LV remodeling was already established. The latter is also consistent with our study in showing no alteration of serotonin content in TAC-induced CHF. As expected, in both studies MAO-A inhibition increased serotonin levels in TAC hearts. Thus, considering that increased cardiac serotonin content is concomitant with improved LV function and absence of remodeling after TAC, an actual beneficial effect of serotonin cannot be excluded. It is plausible that serotonin may sustain cardiac contractility 46 during late stage CHF, particularly if a deficit in NE availability persists. In the end, this effect would provide an additional explanation for the beneficial action of MAO-A inhibition.
There are some limitations to this study. We did not test the role of MAO-B and catechol-O-methyl transferase (COMT), both additional monoamine catabolic enzymes. However, prior studies in mice and humans have not shown a major role for MAO-B in NE catabolism, 36, 37 and COMT gene expression did not change in our TAC model (data not shown). Future studies with pharmacological and genetic ablation of these enzymes will be required to definitively examine their role. The mechanistic intricacies by which MAO-A inhibition preserves NET expression, and likely function (given clorgyline effects on NE content in shams and TAC hearts), warrants further investigation, but a possible major involvement of oxidative/nitrosative stress seems plausible. 47 Fi- indicates relaxation constant; EF, ejection fraction; LVPdia, left ventricular diastolic pressure; LVPsys, left ventricular systolic pressure; LVVed, end-diastolic left ventricular volume; LVVes, end-systolic left ventricular volume; PRSW, preload recruitable stroke work. *PϽ0.05 vs WT sham; †PϽ0.05 TAC vs sham; ‡PϽ0.01 vs WT sham; §PϽ0.05 vs WT TAC; comparison performed by t test (nϭ5 each group). nally, any posttranscriptional and/or posttranslational regulation of MAO-A is currently under investigation.
In conclusion, the present data support MAO-A as an important source of ROS that contributes to maladaptive remodeling and myocardial dysfunction in hearts subjected to hemodynamic stress. The latter likely results in NE-mediated MAO-A activation attributable to depressed neuronal uptake. Whether inhibited ROS production and improved NE cycling/availability are the only keys to interpret the beneficial impact of MAO-A inhibition in pressure overloaded hearts needs further investigation. However, present findings add MAO-dependent signaling as a cause of stress-induced maladaptive hypertrophy and pump failure. The data also suggest that MAO-A inhibitors may prove useful in other models of cardiac failure. In the past, nonselective MAO inhibition was associated with the so-called "cheese reaction," consisting of severe hypertensive crises following the ingestion of food rich in tyramine. 37 However, the generation of new MAO-A inhibitors lacking this limiting side effect makes even more attractive the idea of advancing such therapy for clinical use in CHF patients.
